Objective: To explore the effect of hepatic artery chemotherapy embolization (TACE) combined with positive liver prescription on liver function indicators and tumor markers in patients with primary liver cancer. Methods: A total of 68 patients with primary liver cancer admitted to our hospital from January 2019 to March 2020 was selected as the research subjects, and the patients were divided into two groups, 34 cases each according to the random number table method. The patients in the control group were treated with TACE, and the patients in the observation group were treated with TACE and added positive liver decoction. Observe and compare liver function indicators and tumor markers of the two groups of patients. The flow cytometer was used to detect the immune function of the two groups of patients, and the quality of life score and the TCM syndrome score of the two groups of patients before and after treatment were compared. Results: After treatment, the average ALT, AST, and TBil water of the two groups decreased significantly compared with that before treatment (P<0.05), and the decline of the observation group is greater (P<0.05). After the treatment, the average water of CD3⁺ and CD4⁺ of the two groups of patients increased significantly, and the average water of the patients in the observation group was significantly higher than that of the control group. The differences between the groups were statistically significant (P<0.05). After the treatment of the two groups of patients, the average CD8⁺ water decreased significantly, and the level of CD8⁺ of the patients in the observation group was lower than that of the control group. Compared between the groups, the difference was statistically significant (P<0.05). After treatment, the TCM syndrome score of the patients in the observation group was significantly lower than that before treatment (P<0.05), KPS score increased significantly (P<0.05). Conclusion: TACE combined with positive liver prescription has a significant effect in the treatment of primary liver cancer, and can significantly improve the patient's liver function, reduce the level of tumor markers, and improve the patient's immune function. It is worthy of clinical application.